Abatacept
Approved medicineAlso known as Orencia, Abatacept recombinant.
Recent clinical, regulatory, research and industry developments relating to this drug.
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
CTLA-4 is a second receptor for the B cell activation antigen B7.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy1
- The Journal of experimental medicine1
- Al-Saleh J1
- Balsa A1
- Barile-Fabris L1
- Brady W1
- Damle NK1
- Grosmaire LS1
- Hawes C1
- Horiuchi T1
- Bristol-Myers Squibb Pharmaceutical Research Institute1
- Collegeville1
- Dubai Hospital1
- Hospital de Especialidades Centro Médico Nacional Siglo XXI1
- Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ)1
- Keio University School of Medicine1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 6 of the same disease areas as Abatacept in the shared literature.
Studied across 6 of the same disease areas as Abatacept in the shared literature.
Studied across 6 of the same disease areas as Abatacept in the shared literature.
Studied across 6 of the same disease areas as Abatacept in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature